Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,804 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus - Type 1 Clear all
Completed Phase 1 Interventional

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

NCT05887999
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY3532226, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 17, 2026, 6:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tracking Neurodegeneration in Early Wolfram Syndrome

NCT02455414
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Insipidus, Diabetes Mellitus, Wolfram Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Physician-based Decision Support

NCT03443713
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, MDI, CGM, Exercise
Interventions
Dexcom G6 CGM
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring

NCT04765358
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Virtual Clinic
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

NCT00108004
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Anaheim, California • Escondido, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

NCT02002130
View directory record Official record
Conditions
Type I Diabetes
Interventions
Placebo GABA and Placebo GAD-alum, GABA and Placebo GAD-alum, Active Oral GABA and Active GAD-alum injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Years to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 17, 2026, 6:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes and the Brain in Children

NCT02351466
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Observational
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 16 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Early Phase 1 Interventional

Controlled Insulin Delivery: Combining Technology With Treatment

NCT01484457
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed-loop session
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Overcoming Barriers and Obstacles to Adopting Diabetes Devices

NCT04161131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ONBOARD
Behavioral
Lead sponsor
Molly Tanenbaum
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting Not applicable Interventional

Food and Fitness With Medicine (FFWM)

NCT07027995
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions
Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Columbus, Ohio • Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional

The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM

NCT01697228
View directory record Official record
Conditions
Type 1 Diabetes, Vitamin D Deficiency/Insufficiency
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT00505375
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CTLA-4 Ig, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

NCT00545857
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pioglitazone, Placebo control
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

NCT05422053
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Idaho Falls, Idaho • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 17, 2026, 6:03 AM EDT
Terminated Phase 1 Interventional Results available

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877
View directory record Official record
Conditions
Type 2 Diabetic Nephropathy
Interventions
PF-03882845, Spironolactone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional

GOLO Open-Label Pilot 1

NCT03478202
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
GOLO RELEASE
Dietary Supplement
Lead sponsor
Golo
Industry
Eligibility
18 Years to 69 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Valparaiso, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

NCT01019486
View directory record Official record
Conditions
Coronary Artery Disease, Type 1 Diabetes Mellitus
Interventions
Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 17, 2026, 6:03 AM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 17, 2026, 6:03 AM EDT
Not yet recruiting Not applicable Interventional

Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes

NCT07856836
View directory record Official record
Conditions
Diabetes Type 1
Interventions
Insul-In This Together
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2032
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes

NCT05644730
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Fusion closed loop glucose control system
Device
Lead sponsor
Ideal Medical Technologies
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 17, 2026, 6:03 AM EDT
Not listed Not applicable Interventional

Social Media Use in Adolescent Diabetes Care

NCT06085339
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Social Media
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

NCT02734667
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM at diagnosis of T1D
Device
Lead sponsor
Korey Hood
Other
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

Islet Transplantation in Type 1 Diabetic Kidney Allograft

NCT01241864
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 17, 2026, 6:03 AM EDT